|
1.
|
American Cancer Society: Adult soft tissue
cancer. What are key statistics of soft tissue cancers? http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/detailedguide/sarcoma-adult-soft-tissue-cancer-key-statistics.
Accessed January 21, 2013.
|
|
2.
|
American Cancer Society: Bone cancer. What
are the key statistics about bone cancer? http://www.cancer.org/cancer/bonecancer/detailedguide/bone-cancer-key-statistics.
Accessed January 21, 2013.
|
|
3.
|
Papagelopoulos PJ, Galanis E, Frassica FJ,
Sim FH, Larson DR and Wold LE: Primary fibrosarcoma of bone.
Outcome after primary surgical treatment. Clin Orthop Relat Res.
373:88–103. 2000.PubMed/NCBI
|
|
4.
|
Benassi MS, Gamberi G, Magagnoli G,
Molendini L, Ragazzini P, Merli M, Chiesa F, Balladelli A, Manfrini
M, Bertoni F, Mercri M and Picci P: Metalloproteinase expression
and prognosis in soft tissue sarcomas. Ann Oncol. 12:75–80. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Fidler IJ: Molecular biology of cancer:
invasion and metastasis. Cancer Principles and Practice of
Oncology. De Vita VT, Hellman S and Rosenberg SA: 5th edition.
Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997
|
|
6.
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29(Suppl 16): 15–18. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chambers AF and Matrisian LM: Changing
views on the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kleiner DL and Stetler-Stevenson WG:
Matrix metalloproteinases and metastasis. Cancer Chemother
Pharmacol. 43(Suppl): 42s–51s. 1999. View Article : Google Scholar
|
|
10.
|
Yurchenko PD and Schitny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590.
1990.PubMed/NCBI
|
|
11.
|
Barsky SH, Siegel GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Investig. 49:140–147.
1983.PubMed/NCBI
|
|
12.
|
Liotta LA, Tryggvason K, Garbisa A, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
14.
|
Taubert H, Würl P, Greither T, Kappler M,
Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen
HJ, Magdolen V and Kotzsch M: Co-detection of members of the
urokinase plasminogen activator system in tumour tissue and serum
correlates with a poor prognosis for soft-tissue sarcoma patients.
Br J Cancer. 102:731–737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
16.
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Benassi MS, Magagnoli G, Ponticelli F,
Pazzaglia L, Zanella L, Gamberti G, Ragazzini P, Ferrari C, Mercuri
M and Picci P: Tissue and serum loss of metalloproteinases
inhibitors in high-grade soft tissue sarcomas. Histol Histopathol.
18:1035–1040. 2003.PubMed/NCBI
|
|
18.
|
Dano K, Andreasen PA, Grondahl-Hansen J,
Kristensen P, Nielsen LS and Skriver L: Plasminogen activators,
tissue degradation and cancer. Adv Cancer Res. 44:139–266. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Duffy MJ, Duggan C, Mulcahy HE, McDermott
EW and O'Higgins NJ: Urokinase plasminogen activator: a prognostic
marker in breast cancer including patients with axillary
node-negative disease. Clin Chem. 44:1177–1183. 1998.PubMed/NCBI
|
|
20.
|
Rath M and Pauling L: Plasmin-induced
proteolysis and the role of apoprotein(a), lysine and synthetic
analogs. Orthomolecular Med. 7:17–23. 1992.
|
|
21.
|
Andreasen PA, Kjøller L, Christensen L and
Duffy MJ: The urokinase-type plasminogen activator system in cancer
metastasis: a review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Niedzwiecki A, Roomi MW, Kalinovsky T and
Rath M: Micronutrient synergy - a new tool in effective control of
metastasis and other key mechanisms of cancer. Cancer Metastasis
Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Roebuck MM, Helliwell TR, Chaudhry IH,
Kalogrianitis S, Carter S, Kemp G, Ritchie DA, Jane MJ and Frostick
SP: Matrix metalloproteinase expression is related to angiogenesis
and histologic grade in spindle cell soft tissue neoplasms of the
extremities. Am J Clin Path. 123:405–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Roomi MW, Monterrey JC, Kalinovsky T,
Niedzwiecki A and Rath M: Inhibition of invasion and MMPs by a
nutrient mixture in human cancer cell lines: a correlation study.
Exp Oncol. 32:243–248. 2010.PubMed/NCBI
|
|
25.
|
Roomi MW, Ivanov V, Kalinovsky T, Rath M
and Niedzwiecki A: In vivo and in vitro antitumor effect of
ascorbic acid, lysine, proline, arginine and green tea extract on
human fibrosarcoma cells HT-1080. Med Oncol. 23:105–112. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Roomi MW, Ivanov V, Kalinovsky T,
Niedzwiecki A and Rath M: In vitro and in vivo anti-tumor effect of
a nutrient mixture containing ascorbic acid, lysine, proline and
green tea extract on human synovial sarcoma cancer cells. JAMA.
9:30–34. 2006.
|
|
27.
|
Amin ARMR, Kucek O, Khuri FR and Shin DM:
Perspectives for cancer prevention with natural compounds. J Clin
Oncol. 27:2712–2725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
29.
|
Sun Z, Chen YH, Wang P, Zhang J, Gurewich
V, Zhang P and Liu JN: The blockage of high-affinity lysine binding
sites of plasminogen by EACA significantly inhibits
prourokinase-induced plasminogen activation. Biochem Biophys Acta.
1596:182–192. 2002.
|
|
30.
|
Kemberling JK, Hampton JA, Keck RW, Gomez
MA and Selman SH: Inhibition of bladder tumor growth by the green
tea derivative epigallocatechin-3-gallate. J Urol. 170:773–776.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sato D and Matsushima M: Preventive
effects of urinary bladder tumors induced by
N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves.
Int J Urol. 10:160–166. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Valcic S, Timmermann BN, Alberts DS,
Wachter GA, Krutzsch M, Wymer J and Guillen JM: Inhibitory effect
of six green tea catechins and caffeine on the growth of four
selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Mukhtar H and Ahmed N: Tea polyphenols:
prevention of cancer and optimizing health. Am J Clin Nutr.
71:1698s–1702s. 2000.PubMed/NCBI
|
|
34.
|
Yang GY, Liao J, Kim K, Yurtow EJ and Yang
CS: Inhibition of growth and induction of apoptosis in human cancer
cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Taniguchi S, Fujiki H, Kobayashi H, Go H,
Miyado K, Sadano H and Shimikawa R: Effect of (-) epigallocatechin
gallate, the main constituent of green tea, on lung metastasis with
mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hara Y: Green tea: Health Benefits and
Applications. Marcel Dekker; New York: 2001, View Article : Google Scholar
|
|
37.
|
Kawakami S, Kageyama Y, Fujii Y, Kihara K
and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion
and MMP 9 production of T24 human bladder cancer cells. Anticancer
Res. 21:213–219. 2001.PubMed/NCBI
|
|
38.
|
Morini M, Cai T, Aluigi MG, Noonan DM,
Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The
role of the thiol N-acetyl cysteine in the prevention of tumor
invasion and angiogenesis. Int J Biol Markers. 14:268–271.
1999.PubMed/NCBI
|
|
39.
|
Yoon SO, Kim MM and Chung AS: Inhibitory
effects of selenite on invasion of HT 1080 tumor cells. J Biol
Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Naidu KA, Karl RC and Coppola D:
Antiproliferative and proapoptotic effect of ascorbyl stearate in
human pancreatic cancer cells: association with decreased
expression of insulin-like growth factor 1 receptor. Dig Dis Sci.
48:230–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Anthony HM and Schorah CJ: Severe
hypovitaminosis C in lung-cancer patients: The utilization of
vitamin C in surgical repair and lymphocyte-related host
resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Maramag C, Menon M, Balaji KC, Reddy PG
and Laxmanan S: Effect of vitamin C on prostate cancer cells in
vitro: effect on cell number, viability and DNA synthesis.
Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Koh WS, Lee SJ, Lee H, Park C, Park MH,
Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH:
Differential effects and transport kinetics of ascorbate
derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493.
1998.PubMed/NCBI
|
|
44.
|
Chen Q, Espey MG, Krishna MC, Mitchell JB,
Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic
ascorbic acid concentrations selectively kill cancer cells: action
as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl
Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Nunez C, Ortiz de Apodaca Y and Ruiz A:
Ascorbic acid in the plasma and blood cells of women with breast
cancer. The effect of consumption of food with an elevated content
of this vitamin. Nutr Hosp. 10:368–372. 1995.(In Spanish).
|
|
46.
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineoplastic activity of doxorubicin, cisplatin and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Cooke JP and Dzau VJ: Nitric oxide
synthase: role in the genesis of vascular disease. Annu Rev Med.
48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Roomi MW, Ivanov V, Netke SP, Niedzwiecki
A and Rath M: Serum markers of the liver, heart, and kidney and
lipid profile and histopathology in ODS rats treated with nutrient
synergy. J Am Coll Nutr. 22:477abst 86,. 2003.
|
